Gene transfer with a vector expressing Maxi-K from a smooth muscle-specific promoter restores erectile function in the aging rat

A. Melman, G. Biggs, Kelvin Davies, W. Zhao, Moses T. Tar, G. J. Christ

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Previous reports have demonstrated that gene transfer with the α, or pore-forming, subunit of the human Maxi-K channel (hSlo) restores the decline in erectile capacity observed in established rat models of diabetes and aging. Preliminary data from a human clinical trial also showed safety and potential efficacy in 11 men treated with the same plasmid construct expressing the Maxi-K channel. In all instances, the original plasmid was driven by the heterologous cytomegalovirus promoter which is broadly active in a wide variety of cell and tissue types. To more precisely determine the contribution of the corporal myocyte to the observed physiological effects in vivo, we report here our initial work using a distinct vector (pSMAA-hSlo) in which hSlo gene expression was driven off the mouse smooth muscle α-actin (SMAA) promoter. Specifically, older rats, with diminished erectile capacity, were given a single intracorporal injection with either 100 μg pVAX-hSlo or 10, 100 or 1000 μg pSMAA-hSlo, or vector or vehicle alone. Significantly increased intracavernous pressure (ICP) responses to cavernous nerve stimulation were observed for all doses of both plasmids encoding hSlo, relative to control injections. These data confirm and extend previous observations to document that smooth muscle cell-specific expression of hSlo in corporal tissue is both necessary and sufficient to restore erectile function in aging rats.

Original languageEnglish (US)
Pages (from-to)364-370
Number of pages7
JournalGene Therapy
Volume15
Issue number5
DOIs
StatePublished - Mar 2008

Fingerprint

Large-Conductance Calcium-Activated Potassium Channels
Smooth Muscle
Plasmids
Genes
Injections
Cytomegalovirus
Muscle Cells
Smooth Muscle Myocytes
Actins
Clinical Trials
Safety
Gene Expression
Pressure

ASJC Scopus subject areas

  • Genetics

Cite this

Gene transfer with a vector expressing Maxi-K from a smooth muscle-specific promoter restores erectile function in the aging rat. / Melman, A.; Biggs, G.; Davies, Kelvin; Zhao, W.; Tar, Moses T.; Christ, G. J.

In: Gene Therapy, Vol. 15, No. 5, 03.2008, p. 364-370.

Research output: Contribution to journalArticle

@article{3352d117dfbe4573b1487da87bf607c4,
title = "Gene transfer with a vector expressing Maxi-K from a smooth muscle-specific promoter restores erectile function in the aging rat",
abstract = "Previous reports have demonstrated that gene transfer with the α, or pore-forming, subunit of the human Maxi-K channel (hSlo) restores the decline in erectile capacity observed in established rat models of diabetes and aging. Preliminary data from a human clinical trial also showed safety and potential efficacy in 11 men treated with the same plasmid construct expressing the Maxi-K channel. In all instances, the original plasmid was driven by the heterologous cytomegalovirus promoter which is broadly active in a wide variety of cell and tissue types. To more precisely determine the contribution of the corporal myocyte to the observed physiological effects in vivo, we report here our initial work using a distinct vector (pSMAA-hSlo) in which hSlo gene expression was driven off the mouse smooth muscle α-actin (SMAA) promoter. Specifically, older rats, with diminished erectile capacity, were given a single intracorporal injection with either 100 μg pVAX-hSlo or 10, 100 or 1000 μg pSMAA-hSlo, or vector or vehicle alone. Significantly increased intracavernous pressure (ICP) responses to cavernous nerve stimulation were observed for all doses of both plasmids encoding hSlo, relative to control injections. These data confirm and extend previous observations to document that smooth muscle cell-specific expression of hSlo in corporal tissue is both necessary and sufficient to restore erectile function in aging rats.",
author = "A. Melman and G. Biggs and Kelvin Davies and W. Zhao and Tar, {Moses T.} and Christ, {G. J.}",
year = "2008",
month = "3",
doi = "10.1038/sj.gt.3303093",
language = "English (US)",
volume = "15",
pages = "364--370",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Gene transfer with a vector expressing Maxi-K from a smooth muscle-specific promoter restores erectile function in the aging rat

AU - Melman, A.

AU - Biggs, G.

AU - Davies, Kelvin

AU - Zhao, W.

AU - Tar, Moses T.

AU - Christ, G. J.

PY - 2008/3

Y1 - 2008/3

N2 - Previous reports have demonstrated that gene transfer with the α, or pore-forming, subunit of the human Maxi-K channel (hSlo) restores the decline in erectile capacity observed in established rat models of diabetes and aging. Preliminary data from a human clinical trial also showed safety and potential efficacy in 11 men treated with the same plasmid construct expressing the Maxi-K channel. In all instances, the original plasmid was driven by the heterologous cytomegalovirus promoter which is broadly active in a wide variety of cell and tissue types. To more precisely determine the contribution of the corporal myocyte to the observed physiological effects in vivo, we report here our initial work using a distinct vector (pSMAA-hSlo) in which hSlo gene expression was driven off the mouse smooth muscle α-actin (SMAA) promoter. Specifically, older rats, with diminished erectile capacity, were given a single intracorporal injection with either 100 μg pVAX-hSlo or 10, 100 or 1000 μg pSMAA-hSlo, or vector or vehicle alone. Significantly increased intracavernous pressure (ICP) responses to cavernous nerve stimulation were observed for all doses of both plasmids encoding hSlo, relative to control injections. These data confirm and extend previous observations to document that smooth muscle cell-specific expression of hSlo in corporal tissue is both necessary and sufficient to restore erectile function in aging rats.

AB - Previous reports have demonstrated that gene transfer with the α, or pore-forming, subunit of the human Maxi-K channel (hSlo) restores the decline in erectile capacity observed in established rat models of diabetes and aging. Preliminary data from a human clinical trial also showed safety and potential efficacy in 11 men treated with the same plasmid construct expressing the Maxi-K channel. In all instances, the original plasmid was driven by the heterologous cytomegalovirus promoter which is broadly active in a wide variety of cell and tissue types. To more precisely determine the contribution of the corporal myocyte to the observed physiological effects in vivo, we report here our initial work using a distinct vector (pSMAA-hSlo) in which hSlo gene expression was driven off the mouse smooth muscle α-actin (SMAA) promoter. Specifically, older rats, with diminished erectile capacity, were given a single intracorporal injection with either 100 μg pVAX-hSlo or 10, 100 or 1000 μg pSMAA-hSlo, or vector or vehicle alone. Significantly increased intracavernous pressure (ICP) responses to cavernous nerve stimulation were observed for all doses of both plasmids encoding hSlo, relative to control injections. These data confirm and extend previous observations to document that smooth muscle cell-specific expression of hSlo in corporal tissue is both necessary and sufficient to restore erectile function in aging rats.

UR - http://www.scopus.com/inward/record.url?scp=39449121888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39449121888&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3303093

DO - 10.1038/sj.gt.3303093

M3 - Article

C2 - 18200069

AN - SCOPUS:39449121888

VL - 15

SP - 364

EP - 370

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 5

ER -